Processa Pharmaceuticals to Attend EF Hutton Global Conference

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), based in Hanover, Maryland, is a clinical-stage pharmaceutical company dedicated to developing the next generation of chemotherapeutic drugs that aim to enhance the safety and efficacy of cancer treatments. Recently, the company announced that its management team will be attending the EF Hutton Annual Global Conference on May 15, 2024, at The Plaza Hotel in New York City. The team plans to engage in one-on-one meetings with investors during this event.

Processa Pharmaceuticals focuses on creating innovative oncology treatments by combining proven cancer-killing compounds with their proprietary Regulatory Science Approach. This methodology leverages decades of expertise in defining Optimal Dosage Regimens crucial for obtaining FDA approvals. Their goal is to offer improved therapeutic options to cancer patients and streamline the FDA approval process for their treatments.

One of the key aspects of Processa's innovation lies in their Next Generation Chemotherapy (NGC) drugs. These drugs are essentially modifications of existing FDA-approved oncology medications. The modifications involve altering the metabolism and/or distribution of these drugs while preserving their cancer-killing mechanisms. This unique approach aims to improve the benefit/risk ratio of cancer treatments. Over the years, the Processa team has successfully obtained more than 30 FDA approvals across various divisions, demonstrating their extensive experience and capability.

The Processa team is well-versed in the FDA’s Project Optimus Oncology initiative, which focuses on defining the Optimal Dosage Regimen. Their proven Regulatory Science Approach has shown that fewer patients experience severe side effects leading to dose discontinuation. Additionally, more significant cancer responses are expected, potentially benefiting over 200,000 patients for each NGC drug.

Currently, Processa is developing three key NGC treatments. These include:

1. Next Generation Capecitabine: This treatment, comprising PCS6422 and capecitabine, targets breast, metastatic colorectal, gastrointestinal, pancreatic, and other cancers.

2. Next Generation Gemcitabine: Known as PCS3117, this drug is designed to treat pancreatic, biliary, lung, ovarian, breast, and other cancers.

3. Next Generation Irinotecan: Referred to as PCS11T, it aims to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.

These developments position Processa Pharmaceuticals at the forefront of cancer treatment innovation, with the potential to significantly improve patient outcomes and streamline the treatment approval process.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!